Table 1.
Population demographics of COVID-19 mRNA vaccine study participants.
| Variable * | Total (N = 265) n (%) |
Total (N = 142) n (%) |
||
|---|---|---|---|---|
| 2nd Dose | 3rd Dose | |||
| BNT162b2 | mRNA-1273 | BNT162b2 | mRNA-1273 | |
| Sex | ||||
| Female | 107 (40) | 54 (20) | 33 (23) | 47 (33) |
| Male | 65 (25) | 39 (15) | 30 (21) | 32 (23) |
| Age | ||||
| (Median [range]) | 55 [20–82] | 50 [19–73] | 61 [26–81] | 58 [20–79] |
| Female | ||||
| <65 | 87 (33) | 47 (18) | 21 (15) | 34 (24) |
| ≥65 | 20 (8) | 7 (3) | 12 (8) | 12 (8) |
| Male | ||||
| <65 | 46 (17) | 30 (11) | 18 (13) | 17 (12) |
| ≥65 | 19 (7) | 9 (3) | 12 (9) | 16 (11) |
* Data shown as 2nd- and 3rd-dose population size (N). Sample sizes (n) are shown for sex and age subgroups with percentage of total population size (i.e., females < 65 years old that received a 2nd dose of BNT162b2 [n = 87] compose 33% of the total 2nd-dose population [N = 265]). All subjects included in analyses presented in this manuscript related to vaccine-induced NAbs were SARS-CoV-2 RT-PCR-negative at the time of enrollment and had no known breakthrough infections throughout the remainder of their enrollment. Subjects for which breakthrough infections did occur were included in vaccine-induced NAb data until the timepoint prior to infection, after which data were excluded. Such individuals are included in sample and population sizes above.